Lexaria Bioscience Corp. - Common Stock — Quarterly Cash Flow (NASDAQ:LEXX) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 9.79 M8.68 M6.74 M4.18 M6.05 M6.49 M4.78 M Total liabilities 399.72 K1.92 M1.57 M1.57 M1.53 M277 K437.09 K Total equity 9.39 M6.76 M5.17 M2.6 M4.52 M6.21 M4.34 M Total liabilities & shareholders' equities 9.79 M8.68 M6.74 M4.18 M6.05 M6.49 M4.78 M Total debt ——————— Net debt ———————

News

Lexaria launches 2026 research program for drug delivery tech

Lexaria Bioscience shareholders approve board elections and auditor at annual meeting

Lexaria’s DehydraTECH shows reduced side effects in GLP-1 drugs

Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket - Abivax (NASDAQ:ABVX), Rich Sparkle Holdings (NASDAQ:ANPA)

Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday - Agios Pharmaceuticals (NASDAQ:AGIO), Capital One Finl (NYSE:COF)

Lexaria Bioscience stock price target cut to $1.50 from $4 at H.C. Wainwright

DehydraTECH-semaglutide shows 48% fewer side effects than Rybelsus

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus - Lexaria Bioscience (NASDAQ:LEXX)

Lexaria Bioscience closes $3.5 million registered direct offering

Lexaria Bioscience raises $3.5 million in at-market offering

Lexaria Bioscience stock plunges after $3.5M at-the-market offering

Lexaria Bioscience extends pharmaceutical evaluation agreement